Estimate survival in relapsed/refractory DLBCL
This prognostic tool was developed to provide prognostic information on survival at the time of first progression or relapse for patients with DLBCL who were treated with frontline R-CHOP or like anthracycline based immunochemotherapy. The risk estimations were developed using data from N=1011 patients who progressed after frontline treatment on randomized clinical trials. Observed 2-year survival was higher than predicted by the model when the risk model was applied to two independent cohorts comprised of patients who were not treated on frontline clinical trials. Therapy selection in the relapsed/refractory setting may impact the risk estimates obtained in the model.
MJ Maurer et al.
This prognostic tool was developed to provide prognostic information on survival at the time of first progression or relapse for patients with DLBCL who were treated with frontline R-CHOP or like anthracycline based immunochemotherapy. The risk estimations were developed using data from N=1011 patients who progressed after frontline treatment on randomized clinical trials. Observed 2-year survival was higher than predicted by the model when the risk model was applied to two independent cohorts comprised of patients who were not treated on frontline clinical trials. Therapy selection in the relapsed/refractory setting may impact the risk estimates obtained in the model.
MJ Maurer et al.
© 2020 QxMD Software Inc., all rights reserved. No part of this service may be reproduced in any way without express written consent of QxMD. This information should not be used for the diagnosis or treatment of any health problem or disease. This information is not intended to replace clinical judgment or guide individual patient care in any manner. Click here for full notice and disclaimer.